Glaxo not seeking re-hearing in Ellipta litigation, says Vectura
29th Dec 2020 10:04
(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.
Read moreHikma rallies as it launches generic version of Glaxo asthma treatment
18th Dec 2020 08:12
(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.
Read moreVectura signs asthma treatment deal with Kinaset
30th Nov 2020 08:06
(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.
Read moreCourt denies GSK appeal in Vectura intellectual property dispute
20th Nov 2020 08:34
(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.
Read moreVectura upbeat on EMA nod for 'Enerzair Breezhaler'
1st May 2020 14:30
(Sharecast News) - Inhalation contract manufacturer Vectura Group noted an announcement from Novartis on Friday, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of 'Enerzair Breezhaler'.
Read moreVectura sees FY revenues and earnings 'at least' in line with expectations
13th Jan 2020 08:25
(Sharecast News) - Pharmaceuticals company Vectura said on Monday that its base business had continued to perform well in 2019.
Read moreTuesday broker round up
24th Sep 2019 12:56
(Sharecast News) - TUI: UBS upgrades to neutral with a target price of 900p.
Read moreWednesday broker round-up
11th Sep 2019 13:12
(Sharecast News) - Renew Holdings: Peel Hunt initiates at buy with a target price of 500p.
Read moreVectura trading in line, mulling capital returns
29th May 2019 14:41
(Sharecast News) - Vectura confirmed on Wednesday that its outlook remains in line with guidance for the full year as it said it was considering returning some capital to shareholders.
Read moreWednesday broker round-up
29th May 2019 13:44
(Sharecast News) - Serco: RBC Capital Markets upgrades to outperform with a target price of 150p.
Read moreVectura to take big financial hit as VR475 fails to meed endpoint
26th Nov 2018 10:19
(Sharecast News) - Vectura Group announced on Monday that its phase III study of VR475 in adult and adolescent patients with severe uncontrolled asthma did not meet its primary endpoint.
Read moreVectura's solid interims turn focus further forward
11th Sep 2018 08:18
(Sharecast News) - Vectura kept guidance for the full year unchanged as the inhaled medicines specialist reported robust revenue and said it has identified pipeline projects with potential annual sales of over $250m.
Read moreThursday broker round-up
23rd Aug 2018 14:17
(Sharecast News) - TalkTalk: Barclays upgrades to overweight with a target price of 150p.
Read moreVectura concludes two paediatric studies into VR647
21st Aug 2018 12:31
(Sharecast News) - Vectura announced the successful conclusion of two paediatric studies to support the potential use of VR647, its wholly-owned drug/device combination asset, on Tuesday.
Read moreVectura's GSK royalties agreements firing on all cylinders
16th Feb 2017 07:06
(ShareCast News) - Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts. The cap was equivalent to £9.0m. The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digi
Read more